Early intervention for obsessive compulsive disorder: An expert consensus statement

Naomi A. Fineberg*, Bernardo Dell'Osso, Umberto Albert, Giuseppe Maina, Daniel Geller, Lior Carmi, Nick Sireau, Susanne Walitza, Giacomo Grassi, Stefano Pallanti, Eric Hollander, Vlasios Brakoulias, Jose M. Menchon, Donatella Marazziti, Konstantinos Ioannidis, Annemieke Apergis-Schoute, Dan J. Stein, Danielle C. Cath, Dick J. Veltman, Michael Van AmeringenLeonardo F. Fontenelle, Roseli G. Shavitt, Daniel Costa, Juliana B. Diniz, Joseph Zohar

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

120 Scopus citations

Abstract

Obsessive-compulsive disorder (OCD) is common, emerges early in life and tends to run a chronic, impairing course. Despite the availability of effective treatments, the duration of untreated illness (DUI) is high (up to around 10 years in adults) and is associated with considerable suffering for the individual and their families. This consensus statement represents the views of an international group of expert clinicians, including child and adult psychiatrists, psychologists and neuroscientists, working both in high and low and middle income countries, as well as those with the experience of living with OCD. The statement draws together evidence from epidemiological, clinical, health economic and brain imaging studies documenting the negative impact associated with treatment delay on clinical outcomes, and supporting the importance of early clinical intervention. It draws parallels between OCD and other disorders for which early intervention is recognized as beneficial, such as psychotic disorders and impulsive-compulsive disorders associated with problematic usage of the Internet, for which early intervention may prevent the development of later addictive disorders. It also generates new heuristics for exploring the brain-based mechanisms moderating the ‘toxic’ effect of an extended DUI in OCD. The statement concludes that there is a global unmet need for early intervention services for OC related disorders to reduce the unnecessary suffering and costly disability associated with under-treatment. New clinical staging models for OCD that may be used to facilitate primary, secondary and tertiary prevention within this context are proposed.

Original languageEnglish
Pages (from-to)549-565
Number of pages17
JournalEuropean Neuropsychopharmacology
Volume29
Issue number4
DOIs
StatePublished - Apr 2019

Funding

FundersFunder number
Biohaven Pharmaceuticals
CINP
Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico308237/2014-5
DM-cost
ECNP-NI
FbHealth
IFMAD
ISAD
International College Of OC Spectrum Disorders
Janssen Pharmaceutics
Janssen-Ortho Inc
Kanton Zurich
Neurocrine Bioscience
Shire Canada
Swiss Society for OCD
Wellcome Institute
National Institutes of HealthR21DA042271
U.S. Department of Defense
National Institute of Mental Health
National Institute on Drug Abuse
Eli Lilly and Company
World Health Organization
American Academy of Child and Adolescent Psychiatry
Shire
Pfizer UK
Food and Drug AdministrationAR160104, NCT03202303
Modern Humanities Research Association
National Institute for Health Research
European Commission
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Agència de Gestió d'Ajuts Universitaris i de RecercaNCT03197662, FD-R-05106-01-A4
Instituto de Salud Carlos III
Fundação de Ensino e Pesquisa de Uberaba
Universität Zürich
Universidade do Estado do Rio de Janeiro-26/203.052/2017
European College of Neuropsychopharmacology

    Keywords

    • Compulsive
    • Duration of untreated illness
    • Early intervention
    • OCD
    • Obsessive
    • Staging

    Fingerprint

    Dive into the research topics of 'Early intervention for obsessive compulsive disorder: An expert consensus statement'. Together they form a unique fingerprint.

    Cite this